Copyright © 2003 by the European Society of Cardiology.
Editorial
The final common pathway
Mayo Clinic, School of Medicine, 221 Fourth Avenue SW, 55905 Rochester, MN, USA
Received August 26, 2002;
accepted August 28, 2002
* Tel.: +1-507-284-2504; fax: +1-507-255-2550
holmes.david@mayo.edu
| The first 10% of the full text of this article appears below. |
See doi:10.1016/S1095-668X(02)00429-3for thearticle to which this editorial refers.
Cardiogenic shock remains the final common pathway to death in a substantial number of patients with acute myocardial infarction. We have learned a great deal about this syndrome which at itsbottom line is characterized by a state of severe tissue hypoperfusion.
Much of what we know has come from single centre observational experiences, from multicentre registries, from subsets of patients in randomized trials of acute myocardial infarction therapy, and now from one specific trial of cardiogenic shock.14 Data from
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Cardiogenic shock complicating acute myocardial infarction: Prognostic impact of early and late shock development
- M.G Lindholm, L Køber, S Boesgaard, C Torp-Pedersen, J Aldershvile, and on behalf of the TRACE study group
EHJ 2003 24: 258-265.[Abstract] [FREE Full Text]